Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01515657 · ClinicalTrials.gov registry record · Phase 3
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
A Phase 3 study, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT01515657 is a Phase 3 study that has completed, run by PLx Pharma. The registered enrollment target is 40 participants.
The verdict
NCT01515657, a Phase 3 study, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes.
Interventions
- DRUG PL2200 Aspirin Capsules
- DRUG Enteric-coated aspirin caplets
- DRUG Immediate-Release Aspirin Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01515657
The ClinicalTrials.gov registry entry for NCT01515657 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PL2200 Aspirin Capsules is the first listed.
NCT01515657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01515657 about?
NCT01515657 is a clinical study titled "Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients". This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabet...
What is the current status of trial NCT01515657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2012-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01515657?
The interventions under investigation include: PL2200 Aspirin Capsules (DRUG), Enteric-coated aspirin caplets (DRUG), Immediate-Release Aspirin Tablets (DRUG).
Who is sponsoring clinical trial NCT01515657?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.